Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meeting
2 oral presentations and 5 posters on effectiveness of Prometheus' precision-guided lab services to improve therapeutic intervention for treatment of IBD
SAN DIEGO, May 11, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader of precision healthcare, announced today multiple presentations and posters on precision-guided dosing and monitoring of Inflammatory Bowel Disease (IBD) at the virtual 2021 Digestive Disease Week (DDW) meeting, being held May 21-23. Along with clinical collaborators, Prometheus will present two oral presentations, one during a plenary session; and five posters, two named as Posters of Distinction.
"The data presented at DDW this year represents our commitment to advancing precision-guided clinical testing to optimize individual treatment outcomes," commented Dr. Thierry Dervieux, Chief Scientific Officer. "It also underscores the value of our unparalleled biorepository and database in contributing to the development and validation of novel diagnostic solutions to improve patient outcomes."
The data presented at DDW will include:
- A model-informed precision dosing tool for adalimumab which was developed and evaluated utilizing Prometheus Anser® testing on a clinical cohort of 7,755 IBD patients. Results point to the potential use of such a model to help improve dose optimization; and
- Results from a study evaluating the combination of serum infliximab levels and an endoscopic healing index score with two Prometheus services, Anser and Monitr™, in patients with Crohn's Disease (CD) to guide dose optimization. The data indicates the potential to allow clinicians to distinguish pharmacokinetic from pharmacodynamic failure, and thus guide therapeutic decision-making in patients with CD.
Presentations and posters highlighting data from Prometheus Lab at DDW 2021 are below:
Abstract |
Title |
Date/Time/Session |
Oral Presentation |
||
Plenary session |
HOST SEROREACTIVITY TO MICROBIAL |
Sunday, May 23, 2021 from 3:30 PM to 5:00 PM EDT |
Lecture Presentation |
RISK OF IMMUNOGENICITY TO A SUBSEQUENT |
Sunday, May 23, 2021 from 5:30 PM to |
Posters |
||
Poster of Distinction |
IMPACT OF THIOPURINE EXPOSURE ON |
Sunday, May 23, 2021 from 12:15 PM to |
Poster of Distinction |
DOES PREOPERATIVE SERUM USTEKINUMAB |
Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDT |
Su444 |
MODEL INFORMED PRECISION DOSING OF ADALIMUMAB BY INDIVIDUALIZED PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES |
Sunday, May 23, 2021 from 12:15 PM to |
Su469 |
TUMOR NECROSIS FACTOR IMPACTS INFLIXIMAB CLEARANCE IN INFLAMMATORY BOWEL DISEASES |
Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDT |
Su439 |
THE VALUE OF COMBINED SERUM INFLIXIMAB AND ENDOSCOPIC HEALING INDEX MONITORING FOR GUIDING INFLIXIMAB DOSING IN PATIENTS WITH CROHN'S DISEASE |
Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDT |
The complete abstracts can be found on the DDW 2021 website.
About Prometheus Laboratories
Prometheus Laboratories is a specialty clinical laboratory, which enables precision-guided care in Inflammatory Bowel Disease and other GI disorders. We discover, develop and commercialize testing services that help clinicians improve outcomes across the patient journey, from disease interception and stratification, to therapy selection, optimization and monitoring. For more information, please visit https://www.prometheuslabs.com, visit our virtual booth at DDW 2021, or engage with us on LinkedIn.
About Anser
Anser testing uniquely measures serum drug (infliximab or infliximab biosimilars, adalimumab, ustekinumab, vedolizumab) and antidrug antibody levels using a proprietary, drug tolerant, homogenous mobility shift assay technology. Anser testing aids in the assessment and optimization of biologic therapy management decisions.
About Monitr
Monitr is a first-of-its-kind, non-invasive, multi-protein serum biomarker test developed and validated to assess endoscopic disease activity in patients with CD. The test aids in distinguishing CD patients in endoscopic remission from those with active disease, providing an endoscopic healing index for objective evaluation of mucosal healing.
Investor and Media Contact
Amy Conrad
Juniper Point
(858) 914-1962
[email protected]
SOURCE Prometheus Laboratories, Inc.
